Publications & Presentations

Mar 16, 2022

Functional validation of macrophage subtypes and co-culture models to identify targets in the inflammatory muscle microenvironment

Kelsey DeGouveia, Genevieve Wilson, Richard Lieberman, Eliza Eldredge, Anthony Accorsi

Mar 16, 2022

Identifying Targets to Inhibit Dystrophic Adipogenic Differentiation of Fibro-Adipogenic Progenitors via a Small Molecule Screen

Aidan Bailey, Genevieve Wilson, Richard Lieberman, Johnny Lucas, Joseph Maglio, Erin Valentine, Anthony Accorsi

Mar 16, 2022

Targeting Pathogenic Fibro-Adipogenic Progenitor Cell Differentiation to Promote Muscle Repair

Genevieve Wilson, Alexandria Taylor, Suchi Raghunathan, David Matson, Ivan Efremov, Eliza Eldredge, Anthony Accorsi

Mar 16, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies

Joost Kools, Nicol Voermans, Karlien Mul, Baziel van Engelen, Michelle L. Mellion, John Jiang, Jennifer Shoskes, Kelly Marshall, David Jackson, Yuxi Zhao, Anil Tarachandani, Joanita Figueredo, Damien Eggenspieler

Mar 16, 2022

Feasibility of Measuring Functional Performance of FSHD Patients Using Wearable Sensors to Quantify Physical Activity

Joost Kools, Nicol Voermans, Karlien Mul, Baziel van Engelen, Michelle L. Mellion, John Jiang, Jennifer Shoskes, Kelly Marshall, David Jackson, Yuxi Zhao, Anil Tarachandani, Joanita Figueredo Damien Eggenspieler

Mar 16, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

Dec 11, 2021

In vivo characterization of EED inhibitors, novel small molecule fetal hemoglobin inducers for sickle cell disease

B. Stuart, P. Bruno, K. Xie, I. Efremov, S. Silver, L. Thompson, C. Moxham

Dec 1, 2021

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

Mellion ML, L Ronco, CL Berends, L Pagan, S Brooks, MJ van Esdonk, EMJ van Brummelen, A Odueyungbo, LA Thompson, M Hage, UA Badrising, S Raines, WG Tracewell, B van Engelen, D Cadavid, GJ Groeneveld

Sep 23, 2021

Revolutionizing drug discovery in genetically-defined muscle disease using single-cell and high-dimensional datasets

L. Alejandro Rojas, Ayla Ergun, Caroline Sartain, Anthony Accorsi, Richard Lieberman, Anugraha Raman, Joe Maglio, Erin Valentine, Mary Wertz, Elizabeth Townsend, Damon Polioudakis, Ivan Efremov, Lorin A. Thompson, Serena J. Silver, Christopher M. Moxham

Sep 23, 2021

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, KarlienMul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen